•
Sep 30, 2021

SelectQuote Q1 2022 Earnings Report

SelectQuote reported Q1 2022 results with revenue up 29% year-over-year.

Key Takeaways

SelectQuote's Q1 2022 revenue increased by 29% year-over-year to $159.9 million. The company reported a net loss of $45.4 million and an adjusted EBITDA of $(44.0) million. The full-year guidance remains unchanged.

Consolidated revenue increased by 29% year-over-year to $159.9 million.

Net loss for the quarter was $45.4 million, a decrease of $46.2 million compared to the previous year.

Adjusted EBITDA was $(44.0) million, compared to $12.1 million in the prior year.

SelectRx enrollments are now over 7 times higher than at the time of acquisition.

Total Revenue
$160M
Previous year: $124M
+28.8%
EPS
-$0.28
Previous year: $0.01
-2900.0%
Gross Profit
$67.8M
Previous year: $73.1M
-7.3%
Cash and Equivalents
$184M
Previous year: $305M
-39.9%
Free Cash Flow
-$94.9M
Previous year: -$12.1M
+684.5%
Total Assets
$1.39B
Previous year: $1.11B
+24.8%

SelectQuote

SelectQuote

SelectQuote Revenue by Segment

Forward Guidance

SelectQuote began 2022 with strong results that were ahead of internal expectations, and our full year guidance remains unchanged.

Positive Outlook

  • Strong results that were ahead of internal expectations.
  • Full year guidance remains unchanged.
  • Early progress of Population Health business.
  • SelectRx continues to excel, with daily enrollments now over 7 times higher than the rate of enrollment at the time of our acquisition.
  • SelectQuote is very well positioned for another year of strong revenue and EBITDA growth

Revenue & Expenses

Visualization of income flow from segment revenue to net income